Shares of Misonix, Inc. (NASDAQ:MSON) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $27.00.
A number of research analysts recently issued reports on MSON shares. TheStreet downgraded shares of Misonix from a “c-” rating to a “d” rating in a research note on Thursday, June 20th. BidaskClub upgraded shares of Misonix from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 3rd. Finally, BTIG Research started coverage on shares of Misonix in a research note on Wednesday, June 12th. They issued a “buy” rating and a $29.00 price target for the company.
Misonix stock traded down $1.95 during trading on Friday, reaching $23.90. The stock had a trading volume of 3,067 shares, compared to its average volume of 95,150. Misonix has a 52-week low of $12.91 and a 52-week high of $27.54. The firm has a 50 day moving average of $24.25.
Large investors have recently modified their holdings of the company. Acadian Asset Management LLC lifted its position in shares of Misonix by 15.7% during the 4th quarter. Acadian Asset Management LLC now owns 9,504 shares of the medical equipment provider’s stock worth $153,000 after buying an additional 1,292 shares during the last quarter. Rathbone Brothers plc lifted its position in shares of Misonix by 6.2% during the 1st quarter. Rathbone Brothers plc now owns 15,500 shares of the medical equipment provider’s stock worth $298,000 after buying an additional 900 shares during the last quarter. Tibra Equities Europe Ltd purchased a new stake in shares of Misonix during the 1st quarter worth approximately $327,000. Finally, Geode Capital Management LLC lifted its position in shares of Misonix by 5.3% during the 4th quarter. Geode Capital Management LLC now owns 35,095 shares of the medical equipment provider’s stock worth $561,000 after buying an additional 1,775 shares during the last quarter. Institutional investors and hedge funds own 21.17% of the company’s stock.
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.